Why DonÃ¢ÂÂt Immune Checkpoint Inhibitors Work in Colorectal Cancer?Yuequan Shi1, Zifang Zou1 and David Kerr2*
- *Corresponding Author:
- David Kerr
Radcliffe Department of Medicine
University of Oxford, UK
Received date: April 19, 2017; Accepted date: May 03, 2017; Published date: May 13, 2017
Citation: Shi Y, Zou Z, Kerr D (2017) Why Don’t Immune Checkpoint Inhibitors Work in Colorectal Cancer?. J Gastrointest Cancer Stromal Tumor 2:114. doi:10.4172/2572-4126.1000114
Copyright: © 2017 Shi Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In recent years, immune checkpoint inhibitors have been shown to be effective in treating manifold types of cancer but less robust in colorectal cancer (CRC). While, the subgroup of CRC with microsatellite instability (MSI; also termed as mismatch repair deficient) showed a moderate response to Pembrolizumab in a single arm phase II clinical trial, microsatellite stable (MSS) cancers were unresponsive. Possible mechanisms that affect immune response in colorectal cancer will be reviewed in this article. We will also propose that histone deacetylase (HDAC) inhibition may reverse the immune editing commonly seen in advanced CRC and render them sensitive to immune checkpoint blockade.